Brian T. Gladden - 15 Jun 2026 Form 4 Insider Report for DENTSPLY SIRONA Inc. (XRAY)

Reporting relationship: Director
Issuer ticker: XRAY
Reported as of: 15 Jun 2026
Net transaction value: +$100,000
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:05:22 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jessica Nielsen Causey, Attorney-in-Fact for Brian T. Gladden

Key filing fact

Brian T. Gladden filed Form 4 for DENTSPLY SIRONA Inc. (XRAY) on 15 Jun 2026.

Key facts

This page summarizes Brian T. Gladden's Form 4 filing for DENTSPLY SIRONA Inc. (XRAY).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 17:05.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: +$100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001435432 Primary reporting owner

Gladden Brian T

Relationship: Director
Address: C/O DENTSPLY SIRONA INC, 13320-B BALLANTYNE CORPORATE PLACE, CHARLOTTE
Signature: /s/ Jessica Nielsen Causey, Attorney-in-Fact for Brian T. Gladden
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XRAY transaction

Common Stock

Purchase

Transaction value: $100,000
Shares: +9,985
Change %: +19%
Price: $10.02
Shares after: 61,849
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.015 to 10.0156, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.